London, United Kingdom
CHARM Therapeutics, founded in 2021 and headquartered in the United Kingdom, is at the forefront of innovation in the AI, Biotechnology, and Life Sciences industries. Guided by the slogan, "Protein-ligand intelligence to deliver next generation small molecule therapeutics," the company is pioneering the development of novel treatments for acute myeloid leukemia (AML).
Their leading program focuses on a groundbreaking, next-generation menin inhibitor. Unlike existing solutions that struggle with resistance mutations, CHARM's candidate maintains potency against all known clinical resistance mutations, offering a potential breakthrough for achieving long-lasting treatment responses in AML patients.
Recently, CHARM Therapeutics secured an $80.00M Series B investment on 01 September 2025, attracting a strong consortium of investors, including F-Prime Capital, Khosla Ventures, Nvidia, OrbiMed, NEA, and SR One. This robust funding highlights the confidence and strategic interest from prominent venture capital in the company's compelling vision and technological advancement.
